A Study on the Bone-health Effectiveness of Applying Recombinant Factor VIII Fc (rFVIIIFc) to Patients With Hemophilia A (Prototype A)

RecruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

July 14, 2023

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Severe Hemophilia A Without Inhibitor

Interventions

DIAGNOSTIC_TEST

serum biomarker.

serum biomarker:CTX-II, COMP, hsCRP, TNF-a, CTX-I, sRANKL, OPG, and Osteopontin (OPN)

Trial Locations (1)

RECRUITING

Tri-Service General Hospital Hemophilia Care Center, Taipei

All Listed Sponsors

lead

Tri-Service General Hospital

OTHER